Marc Tessier-Lavigne
CIK 1437435 · EVP, RESEARCH DRUG DISCOVERY · last filed 2025-06-05
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$44.07M
Companies
6
Total Filings
62
Lifetime Open-Market Net
-$93.00M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| DNLI | Director | 1,965,424 | $21.66 | $42.57M | -$36.87M | 25 | 2025-06-05 |
| REGN | Director | 2,434 | $612.14 | $1.49M | -$54.63M | 25 | 2023-01-05 |
| AGIO | Director | — | $29.46 | — | $0 | 3 | 2016-06-23 |
| Juno Therapeutics, Inc. (JUNO) Delisted | Director | 250,000 | — | — | $0 | 3 | 2016-06-21 |
| PFE | Director | — | $26.21 | — | $0 | 4 | 2015-04-24 |
| DNA | EVP, RESEARCH DRUG DISCOVERY | 1,159 | $7.89 | $9.1K | -$1.50M | 1 | 2008-07-18 |
Recent Filings · Page 7 of 7
62 filingsForm 4 transactions across all companies, newest first.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2009-03-30 | — | Disp (D) | −1,159 | -$110.1K | |
| 2008-07-18 | DNA | Mixed | — | -$500.1K | EDGAR |
Showing 61–62 of 62
Prev
Page 7 of 7
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.